Education
About Us
Working with TipRanks
Follow Us
AlzeCure Pharma AB (DE:AC6)
:AC6
RESEARCH TOOLSreports
AC6 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.04 - €0.44
Previous CloseN/A
Volume0.00
Average Volume (3M)207.00
Market Cap
€37.70M
Enterprise Value€234.65M
Total Cash (Recent Filing)€20.82M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Nov 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding114,914,450
10 Day Avg. Volume399
30 Day Avg. Volume207
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.04 and its highest was €0.44 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €37.70M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is Nov 11, 2025 which is in 75 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on Aug 26, 2025. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 114,914,450 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.